Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known
beneficial effects on glucose metabolism. Evidence from animal models and in vitro studies
suggest that in addition to its effects on glucose metabolism, metformin may influence
metabolic and cellular processes associated with the development of age-related conditions,
such as inflammation, oxidative damage, diminished autophagy, cell senescence and apoptosis.
As such, metformin is of particular interest in clinical translational research in aging
since it may influence fundamental aging factors that underlie multiple age-related
conditions. The investigators therefore propose a pilot study to examine the effect of
metformin treatment on the biology of aging in humans. Namely, whether treatment with
metformin will restore the gene expression profile of older adults with impaired glucose
tolerance (IGT) to that of young healthy subjects.
Phase:
Phase 4
Details
Lead Sponsor:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University